Compare MLCO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | ANIP |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Hong Kong | United States |
| Employees | 22961 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2006 | 1999 |
| Metric | MLCO | ANIP |
|---|---|---|
| Price | $4.24 | $73.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $7.06 | ★ $105.78 |
| AVG Volume (30 Days) | ★ 1.8M | 345.1K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $1.93 | $24.85 |
| Revenue Next Year | $4.38 | $10.76 |
| P/E Ratio | ★ $12.16 | $31.03 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $4.07 | $69.58 |
| 52 Week High | $9.53 | $96.99 |
| Indicator | MLCO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 50.75 |
| Support Level | $4.07 | $73.71 |
| Resistance Level | $5.73 | $83.03 |
| Average True Range (ATR) | 0.15 | 2.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 24.24 | 34.59 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.